Mohammed Inayathullah

Dr. Mohammed Inayathullah

Stanford University School of Medicine
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2013 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
WTWen Tian
Wen Tian
XJXinguo Jiang
Xinguo Jiang
RTRasa Tamosiuniene
Rasa Tamosiuniene
YSYon K. Sung
Yon K. Sung
JQJin Qian
Jin Qian
MNMark R Nicolls
Mark R Nicolls
In a rat model of pulmonary hypertension, inhibition of LTB 4 synthesis in macrophages that accumulate in lung tissue reverses the disease.

22 December 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
DDDominik Duscher
Dominik Duscher
ENEvgenios Neofytou
Evgenios Neofytou
VWVictor W. Wong
Victor W. Wong
ZMZeshaan Maan
Zeshaan Maan
RRRobert C. Rennert
Robert C. Rennert
GGGeoffrey C. Gurtner
Geoffrey C. Gurtner
Significance: Diabetes is the leading cause of nontraumatic amputations. There are no effective therapies to prevent diabetic ulcer formation and only modestly effective technologies to help with their healing. To enhance diabetic wound healing we designed a transdermal delivery system containing the FDA-approved small molecule deferoxamine, an iron chelator that increases defective hypoxia inducible factor-1 alpha transactivation in diabetes by preventing iron-catalyzed reactive oxygen stress. This system overcomes the challenge of delivering hydrophilic molecules through the normally impermeable stratum corneum and both prevents diabetic ulcer formation and improves the healing of existing diabetic wounds. This represents a prophylactic pharmacological agent to prevent ulcer formation that is rapidly translatable into the clinic and has the potential to ultimately transform the care and prevention of diabetic complications.

29 December 2021 in Biomaterials
Verified
Journal Article
Closed access
AKAzadeh Kheirolomoom
Azadeh Kheirolomoom
AKAris J. Kare
Aris J. Kare
EIElizabeth S. Ingham
Elizabeth S. Ingham
RPRamasamy Paulmurugan
Ramasamy Paulmurugan
ERElise R. Robinson
Elise R. Robinson
KFKatherine W. Ferrara
Katherine W. Ferrara

13 January 2009 in Acta Neuropathologica
Verified
Journal Article
Open access
PDF file
JZJustin Zaghi
Justin Zaghi
BGBen Goldenson
Ben Goldenson
MIMohammed Inayathullah
Mohammed Inayathullah
ALAlbert S. Lossinsky
Albert S. Lossinsky
AMAva Masoumi
Ava Masoumi
MFMilan Fiala
Milan Fiala
Neuronal accumulation of oligomeric amyloid-β (Αβ) is considered the proximal cause of neuronal demise in Alzheimer disease (AD) patients. Blood-borne macrophages might reduce Aβ stress to neurons by immigration into the brain and phagocytosis of Αβ. We tested migration and export across a blood-brain barrier model, and phagocytosis and clearance of Αβ by AD and normal subjects’ macrophages. Both AD and normal macrophages were inhibited in Αβ export across the blood-brain barrier due to adherence of Aβ-engorged macrophages to the endothelial layer. In comparison to normal subjects’ macrophages, AD macrophages ingested and cleared less Αβ, and underwent apoptosis upon exposure to soluble, protofibrillar, or fibrillar Αβ. Confocal microscopy of stained AD brain sections revealed oligomeric Aβ in neurons and apoptotic macrophages, which surrounded and infiltrated congophilic microvessels, and fibrillar Aβ in plaques and microvessel walls. After incubation with AD brain sections, normal subjects’ monocytes intruded into neurons and uploaded oligomeric Aβ. In conclusion, in patients with AD, macrophages appear to shuttle Aβ from neurons to vessels where their apoptosis may release fibrillar Aβ, contributing to cerebral amyloid angiopathy.

23 May 2017 in Journal of Materials Chemistry B
Verified
Journal Article
Closed access
PDF file
MMM. Rezaa Mohammadi
M. Rezaa Mohammadi
ANAmirali Nojoomi
Amirali Nojoomi
MMMasoud Mozafari
Masoud Mozafari
ADArita Dubnika
Arita Dubnika
MIMohammed Inayathullah
Mohammed Inayathullah
Jayakumar RajadasJayakumar Rajadas
Jayakumar Rajadas
Nanoscale hybridization to fabricate all-in-one nanoparticles for superior targeted delivery systems.

1 October 2008 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
GYGhiam Yamin
Ghiam Yamin
KOKenjiro Ono
Kenjiro Ono
MIMohammed Inayathullah
Mohammed Inayathullah
DTDavid Teplow
David Teplow
Alzheimers disease (AD), the most common neurodegenerative disorder in the aged, is characterized by the cerebral deposition of fibrils formed by the amyloid β-protein (Aβ), a 40-42 amino acid peptide. The folding of Aβ into neurotoxic oligomeric, protofibrillar, and fibrillar assemblies is hypothesized to be the key pathologic event in AD. Aβ is formed through cleavage of the Aβ precursor protein by two endoproteinases, β-secretase and γ-secretase, that cleave the Aβ N-terminus and C-terminus, respectively. These facts support the relevance of therapeutic strategies targeting Aβ production, assembly, clearance, and neurotoxicity. Currently, no disease-modifying therapeutic agents are available for AD patients. Instead, existing therapeutics provide only modest symptomatic benefits for a limited time. We summarize here recent efforts to produce therapeutic drugs targeting Aβ assembly. A number of approaches are being used in these efforts, including immunological, nutraceutical, and more classical medicinal chemical (peptidic inhibitors, carbohydratecontaining compounds, polyamines, “drug-like” compounds, chaperones, metal chelators, and osmolytes), and many of these have progressed to phase III clinical trails. We also discuss briefly a number of less mature, but intriguing, strategies that have therapeutic potential. Although initial trials of some disease-modifying agents have failed, we argue that substantial cause for optimism exists.